Table 1 Demographic and clinical characteristics
Characteristic | RA patients (n = 60) | Controls (n = 60) | p-value |
|---|---|---|---|
Age years, mean ± SD | 54.37 ± 8.88 | 54.83 ± 6.62 | 0.750 |
Female, n (%) | 56 (93.3) | 56 (93.3) | 1.000 |
T2DM, n (%) | 10 (16.7) | 9 (15.0) | 0.803 |
Hypertension, n (%) | 20 (33.3) | 20 (33.3) | 1.000 |
Dyslipidemia, n (%) | 21 (35.0) | 21 (35.0) | 1.000 |
Obesity, n (%) | 25 (41.7) | 24 (40.0) | 0.853 |
BMI, median (IQR) | 28.90 (26.39–33.78) | 27.99 (24.90-32.87) | 0.187 |
Active smoking, n (%) | 4 (6.7) | 5 (8.3) | 1.000 |
Antidiabetic treatment, n (%) | 10 (16.7) | 8 (13.3) | 0.609 |
Antihypertensive treatment, n (%) | 16 (26.7) | 18 (30.0) | 0.685 |
Statins, n (%) | 13 (21.7) | 13 (21.7) | 1.000 |
Disease duration, mean ± SD | 2.66 ± 1.39 | - | - |
Symptom duration, median (IQR) | 3.41 (2.58-5.00) | - | - |
DAS28-CRP, median (IQR) | 3.36 (2.00-4.20) | - | - |
DAS28-CRP, n (%) | |||
Remission | 21 (35.0) | - | - |
Low disease activity | 7 (11.7) | - | - |
Moderate disease activity | 26 (43.3) | - | - |
High disease activity | 6 (10.0) | - | - |
CRP, median (IQR) | 0.79 (0.46–1.36) | - | - |
ESR, median (IQR) | 20.00 (13.00–37.00) | - | - |
Seropositivity, n (%) | |||
RF | 42 (70.0) | - | - |
Anti-CCP antibodies | 27 (45.0) | - | - |
MTX, n (%) | 44 (73.3) | - | - |
bDMARD, n (%) | 4 (6.7) | - | - |
Glucocorticoids, n (%) | 34 (56.7) | - | - |
Dosage mg, median (IQR) | 5.00 (5.00-8.12) | - | - |
Duration years, mean ± SD | 1.68 ± 1.40 | - | - |